Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis

JAMA

Volumn 300, Issue 20, 2008, Pages 2407-2416

  Drummond, M Bradley ^a   Dasenbrook, Elliott C ^a   Pitz, Marshall W ^b   Murphy, David J ^a   Fan, Eddy ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

ADVERSE OUTCOME; CHRONIC OBSTRUCTIVE LUNG DISEASE; CINAHL; CLINICAL TRIAL; DRUG DOSE REGIMEN; EMBASE; EVENING DOSAGE; EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FRACTURE; HUMAN; MEDLINE; META ANALYSIS; MORNING DOSAGE; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; PSYCINFO; QUANTITATIVE ANALYSIS; RANDOM SAMPLE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 57049135358     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.717     Document Type: Review

References (47)

1. Wilt TJ, Niewoehner D, Kim C, et al. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Evid Rep Technol Assess (Summ). 2005;(121):1-7.
2. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005;294(10):1255-1259.
3. Heron MP, Smith BL. Deaths: leading causes for 2003. Natl Vital Stat Rep. 2007;55:1-92.
4. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93(3):391-398.
5. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party. Lancet. 1981;1(8222):681-686.
6. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233-239.
7. Grimes GC, Manning JL, Patel P, Via RM. Medications for COPD: a review of effectiveness. Am Fam Physician. 2007;76(8):1141-1148.
8. Hanania NA, Sharafkhaneh A. Update on the pharmacologic therapy for chronic obstructive pulmonary disease. Clin Chest Med. 2007;28(3):589-607.
9. Heaney LG, Lindsay JT, McGarvey LP. Inflammation in chronic obstructive pulmonary disease: implications for new treatment strategies. Curr Med Chem. 2007;14(7):787-796.
10. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297-1303.
11. Calverley P, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease [published correction appears in Eur Resp J. 2004;24(6):1075]. Eur Respir J. 2003;22(6):912-919.
12. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
13. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(2):144-149.
14. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74-81.
15. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19-26.
16. Zheng JP, Yang L, Wu YM, et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest. 2007;132(6):1756-1763.
17. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-555.
18. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.
19. Hubbard R, Tattersfield A, Smith C, West J, Smeeth L, Fletcher A. Use of inhaled corticosteroids and the risk of fracture. Chest. 2006;130(4):1082-1088.
20. Pujades-Rodriguez M, Smith CJ, Hubbard RB. Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease. QJM. 2007;100(8):509-517.
21. Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med. 2006;4(3):253-262.
22. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;(4):CD003794.
23. Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;(2):CD002991.
24. Cazzola M, Matera MG. To add, or not to add an inhaled corticosteroid in moderate COPD: that is the question. Chest. 2008;134(2):223-225.
25. Suissa S. Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs. Am J Respir Crit Care Med. 2008;178(4):322-323.
26. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement: quality of reporting of meta-analyses. Lancet. 1999;354(9193):1896-1900.
27. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-469.
28. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.
29. Blais R, Gregoire JP, Rouleau R, Cartier A, Bouchard J, Boulet LP. Ambulatory use of inhaled beta(2)-agonists for the treatment of asthma in Quebec: a population-based utilization review. Chest. 2001;119(5):1316-1321.
30. Higgins J, Altman DG. Assessing risk of bias in included studies. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0. Oxford, UK: The Cochrane Collaboration; February 2008.
31. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
33. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.
34. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343(26):1902-1909.
35. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545-555.
36. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340(25):1948-1953.
37. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353(9167):1819-1823.
38. Woodhead M. Inhaled corticosteroids cause pneumonia . . . or do they? Am J Respir Crit Care Med. 2007;176(2):111-112.
39. Turner MO. Inhaled corticosteroids and pneumonia in COPD: an association looking for evidence. Am J Respir Crit Care Med. 2008;177(5):555-556.
40. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176(2):162-166.
41. Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J. 2006;27(6):1210-1216.
42. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J. 2006;28(2):346-351.
43. Whitford H, Orsida B, Kotsimbos T, et al. Bronchoalveolar lavage cellular profiles in lung transplantation: the effect of inhaled corticosteroids. Ann Transplant. 2000;5(3):31-37.
44. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(11):1207-1214.
45. Wyss D, Bonneau O, Trifilieff A. Synergistic effect of formoterol and mometasone in a mouse model of allergic lung inflammation. Br J Pharmacol. 2007;152(1):83-90.
46. Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003;112(1):29-36.
47. Weatherall M, James K, Clay J, et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy. 2008;38(9):1451-1458.